BTIG analyst Julian Harrison raised the firm’s price target on Cullinan Therapeutics (CGEM) to $38 from $32 and keeps a Buy rating on the shares. The firm recently caught up with Cullinan management, saying it believes CLN-049 is worth a second look ahead of the company’s podium presentation on December 8. The firm added CLN-049 into its model, with a 65% probability of success.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management Ends Development of CLN-617
- Promising Developments and Strategic Partnerships Boost Cullinan Management’s Growth Prospects
- Taiho, Cullinan Therapeutics initiate rolling submission of NDA for zipalertinib
- Optimistic Buy Rating for Cullinan Management Driven by Promising Drug Pipeline and Upcoming Catalysts
- Cullinan Therapeutics price target raised to $26 from $24 at H.C. Wainwright